VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 790.00K | 721.00K | 646.00K | 486.00K | 698.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 790.00K | 721.00K | 646.00K | 486.00K | 698.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 790.00K | 721.00K | 646.00K | 486.00K | 698.00K |
| SG&A Expenses | 18.67M | 17.09M | 16.89M | 17.08M | 16.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.69M | 66.19M | 60.29M | 56.46M | 53.54M |
| Operating Income | -69.90M | -65.47M | -59.65M | -55.97M | -52.84M |
| Income Before Tax | -67.05M | -62.24M | -55.77M | -51.41M | -47.30M |
| Income Tax Expenses | 0.00 | 0.00 | 7.00K | 7.00K | 8.00K |
| Earnings from Continuing Operations | -67.05 | -62.24 | -55.78 | -51.42 | -47.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.05M | -62.24M | -55.78M | -51.42M | -47.30M |
| EBIT | -69.90M | -65.47M | -59.65M | -55.97M | -52.84M |
| EBITDA | -69.71M | -65.30M | -59.49M | -55.82M | -52.69M |
| EPS Basic | -1.90 | -1.91 | -1.79 | -1.66 | -1.54 |
| Normalized Basic EPS | -1.18 | -1.19 | -1.12 | -1.04 | -0.97 |
| EPS Diluted | -1.90 | -1.91 | -1.79 | -1.66 | -1.54 |
| Normalized Diluted EPS | -1.18 | -1.19 | -1.12 | -1.04 | -0.97 |
| Average Basic Shares Outstanding | 141.47M | 129.95M | 124.83M | 123.51M | 122.47M |
| Average Diluted Shares Outstanding | 141.47M | 129.95M | 124.83M | 123.51M | 122.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |